EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Divergent Biologic Responses in Chronic Rhinosinusitis with Nasal Polyps: Mechanisms of Residual Disease and Longitudinal Management

Huikang Wang, Xinjun Xu, Xicheng Song, Yu Zhang

Journal of Asthma and Allergy · 2026-11 · Volume 19 · 1-21

DOI: 10.2147/jaa.s647286 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Asthma and Allergy, 2026-11. Verfasst von Huikang Wang und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Biologics improve polyp burden, congestion, smell, quality of life, and rescue-treatment outcomes in severe chronic rhinosinusitis with nasal polyps (CRSwNP), yet individual responses remain heterogeneous and frequently discordant across clinical domains. This narrative Review examines why trial-level efficacy does not consistently become multidomain disease control. We propose that residual burden arises from five interacting sources: persistent or parallel inflammation, slowly reversible tissue remodeling, anatomy or impaired topical access, olfactory-compartment injury, and implementation failure. Epithelial alarmins, interleukin (IL)-4/IL-13 signaling, immunoglobulin E, eosinophil states, stromal programs, mixed or non-type 2 inflammation, and olfactory epithelial injury overlap rather than define mutually exclusive endotypes. Consequently, blood or tissue biomarkers can support a treatment hypothesis but do not yet predict the superior biologic for an individual patient. Randomized trials establish efficacy for several targets, whereas indirect comparisons, switching cohorts, interval-extension studies, and withdrawal data answer different and less certain questions. We therefore frame biologic treatment as a longitudinal experiment: define the patient-valued target, verify exposure and background care, measure domain-specific trajectories, explain residual disease, and match the next action to the unresolved mechanism. Emotional distress, adherence, affordability, and access are integrated within implementation failure because they determine whether pharmacological efficacy becomes durable real-world control. Future studies should prioritize treatment-interaction biomarkers, tissue-informed response phenotypes, direct comparisons, adaptive sequencing trials, and explicit definitions of on-treatment and treatment-free remission. Keywords: chronic rhinosinusitis with nasal polyps, biologics, response heterogeneity, type 2 inflammation, treatable traits, disease control

Zitieren

APA

Wang, H., Xu, X., Song, X., & Zhang, Y. (2026). Divergent Biologic Responses in Chronic Rhinosinusitis with Nasal Polyps: Mechanisms of Residual Disease and Longitudinal Management. Journal of Asthma and Allergy, Volume 19, 1-21. https://doi.org/10.2147/jaa.s647286

Vancouver

Wang H, Xu X, Song X, Zhang Y. Divergent Biologic Responses in Chronic Rhinosinusitis with Nasal Polyps: Mechanisms of Residual Disease and Longitudinal Management. Journal of Asthma and Allergy. 2026;Volume 19:1-21. doi:10.2147/jaa.s647286

BibTeX
@article{Wang2026,
  author = {Wang, Huikang and Xu, Xinjun and Song, Xicheng and Zhang, Yu},
  title = {Divergent Biologic Responses in Chronic Rhinosinusitis with Nasal Polyps: Mechanisms of Residual Disease and Longitudinal Management},
  journal = {Journal of Asthma and Allergy},
  year = {2026},
  volume = {Volume 19},
  pages = {1--21},
  doi = {10.2147/jaa.s647286}
}
Kostenlos starten →